INTRODUCTION: Calretinin, a calcium-binding protein, has been reported to be an important new marker in Hirschsprung's disease (HD). The aim is to study the diagnostic value of Calretinin in total colonic aganglionosis (TA), prematurity, and superficial biopsy when nerve hyperplasia may not be accessed by ACE activity. METHODS: Records of patients diagnosed with HD at our institution from 1985 to 2010 were studied and patients with TA identified. We examined tissue samples from those TA, partial colectomies for HD, biopsies for suspicion of HD, and rectal tissue from aborted fetuses. Immunohistochemical analysis of Calretinin was compared with ACE gold standard method in all cases. RESULTS: In the majority of the cases, the diagnosis was ascertained by ACE activity and Calretinin staining. However, in 9 cases, the diagnosis was possible with Calretinin staining but not with ACE: in 4 TA because of the absence of nerve hyperplasia, and in 5 cases because the biopsies were too superficial to examine the nerve hyperplasia. In addition, Calretinin was expressed in the gut as early as 22 gestational weeks. CONCLUSION: The use of Calretinin staining may be superior to ACE activity, particularly in the context of TA, superficial biopsies, and prematurity, allowing earlier diagnosis.
INTRODUCTION:Calretinin, a calcium-binding protein, has been reported to be an important new marker in Hirschsprung's disease (HD). The aim is to study the diagnostic value of Calretinin in total colonic aganglionosis (TA), prematurity, and superficial biopsy when nerve hyperplasia may not be accessed by ACE activity. METHODS: Records of patients diagnosed with HD at our institution from 1985 to 2010 were studied and patients with TA identified. We examined tissue samples from those TA, partial colectomies for HD, biopsies for suspicion of HD, and rectal tissue from aborted fetuses. Immunohistochemical analysis of Calretinin was compared with ACE gold standard method in all cases. RESULTS: In the majority of the cases, the diagnosis was ascertained by ACE activity and Calretinin staining. However, in 9 cases, the diagnosis was possible with Calretinin staining but not with ACE: in 4 TA because of the absence of nerve hyperplasia, and in 5 cases because the biopsies were too superficial to examine the nerve hyperplasia. In addition, Calretinin was expressed in the gut as early as 22 gestational weeks. CONCLUSION: The use of Calretinin staining may be superior to ACE activity, particularly in the context of TA, superficial biopsies, and prematurity, allowing earlier diagnosis.
Authors: Yunmin Li; Tatsuo Kido; Maria M Garcia-Barcelo; Paul K H Tam; Z Laura Tabatabai; Yun-Fai Chris Lau Journal: Hum Mol Genet Date: 2014-09-28 Impact factor: 6.150
Authors: Roxana Rassouli-Kirchmeier; Maarten Janssen Lok; Benno Kusters; Iris Nagtegaal; Nils Köster; Herjan van der Steeg; Marc Wijnen; Ivo de Blaauw Journal: Pediatr Surg Int Date: 2014-07-05 Impact factor: 1.827
Authors: Sarath Kumar Narayanan; Soundappan S Soundappan; Edwin Kwan; Ralph C Cohen; Amanda Charlton; Daniel T Cass Journal: Pediatr Surg Int Date: 2015-11-02 Impact factor: 1.827
Authors: Kristy Dm Wittmeier; Kendall Hobbs-Murison; Cindy Holland; Elizabeth Crawford; Hal Loewen; Melanie Morris; Suyin Lum Min; Ahmed Abou-Setta; Richard Keijzer Journal: J Med Internet Res Date: 2018-12-21 Impact factor: 5.428